Vireo Health of New York CEO Ari Hoffnung responds to Governor Cuomo and Mayor De Blasio’s 10-Point Plan to Transform and Fund the MTA

The following statement can be attributed to Ari Hoffnung, Chief Executive Officer of Vireo Health of New York, one of only 10 organizations licensed in the state to grow, cultivate, manufacture and sell medical cannabis:

*****

“A sensible adult-use program should be able to generate sufficient tax revenues to fund much needed subway improvements and programs designed to benefit those communities disproportionately adversely impacted by the War on Drugs.”

You can read Mr. Hoffnung’s response to Gov. Cuomo’s initial plan to legalize adult-use, recreational cannabis here. You can also read his statements to the New York State Assembly here.

###

About Vireo Health of New York

VireoHealth of New York is a physician-led company dedicated to providing best-in-class cannabis-based medications and compassionate care.The Company is a proven leader in the field of medical marijuana. In December 2015, Vireo’s products became the first to be certified Kosher by the Orthodox Union.In addition to brick-and-mortar dispensary locations, Vireo launched the first medical marijuana home delivery service in the New York City area, now available throughout New York City, Westchester, Rockland, Putnam, Nassau and parts of Suffolk County.For more information, visithttps://vireohealth.com/ny/.

America Began Alcohol Prohibition in 1919 but It’s Edging Toward Ending Cannabis Prohibition in 2019

What a difference a century makes.

One hundred years after the 18th Amendment took effect and prohibition of alcohol became the law of the land, 2019 is likely to be among the most significant years in U.S. history for the ongoing battle to end cannabis prohibition. That’s not to say 2018 (or 2017 or 2016, and so on) wasn’t important. But the cannabis industry seems poised for such significant growth that it’s inevitable that every new year will outpace the previous one.

Here are some key themes and events sure to shape the industry in 2019.

State Policy

The November midterm elections were a major victory for cannabis advocates, with Michigan becoming the first state in the Midwest to legalize adult use of cannabis, voters in Missouri and Utah approving initiatives to allow statewide medicinal cannabis use, and candidates from New Mexico to New York focusing their agendas on the economic impact and social justice ramifications of cannabis legalization.

We’re watching closely what will happen here in New York, where Gov. Andrew Cuomo made legalization of adult-use cannabis a key piece of his agenda for the first 100 days of his third term. With Democrats taking control of the state Legislature in 2019 and neighboring Massachusetts seeing recreational dispensaries open for the first time in 2018, there will be both pressure and momentum for New York to follow suit.

New York has an opportunity to become a national leader in righting the injustices of the war on drugs, which for decades has unfairly targeted minority communities. In doing so, New York can become a leader among states that previously legalized adult-use cannabis. A few potential measures could include:

  • Offering low-interest loans to minority- and women-owned certified businesses;
  • Offering priority license registration to victims of the war on drugs;
  • Mandating that cannabis companies provide annual diversity reports on their workforces and contracts;
  • Allocating a portion of cannabis tax revenues to fund scholarships for formerly incarcerated individuals;
  • Encouraging unionization to ensure that jobs in the cannabis industry offer fair wages and good benefits.

Doing so will set a national standard for equality and justice as more states come online.

Across the Hudson in New Jersey, adult-use legislation did suffer a setback last year. With that said, the Garden State will likely reconsider adult-use legislation early in 2019 and most believe it will succeed.

Tax revenues certainly will drive more states to consider adult-use legislation. A report from the Cato Institute projects that the legalization and fair taxation of cannabis could generate more than $100 billion annually for federal, state and local governments. A similar report forecasts that up to 1 million new jobs could be created nationwide within the first 10 years of adult-use legalization

Federal Policy

Although significant progress is being made at the state level, not much has happened on the federal level. With Democrats taking control of the House, there will be Congressional hearings on cannabis policy and multiple pieces of legislation that are supportive of the industry on issues such as banking and taxation.

The real question is whether there is any cannabis legislation that the Republican controlled Senate would pass and President Donald Trump would sign into law. I believe the answer is yes, and that bill would likely be modeled after the STATES Act, which defers the issue of cannabis policy to each state.

Passing the STATES Act should receive strong bipartisan support. An October Gallup Poll showed almost 66 percent of Americans support legalizing cannabis. Other national polls show almost 90 percent of Americans support medical cannabis.

Politically, by passing the STATES Act, Senate Republicans could prevent cannabis from becoming a problematic issue in 2020 and provide an opportunity for the party to demonstrate its commitment to state rights.

Let’s not forget that during the 2016 presidential elections, Michigan, Pennsylvania, Ohio, Florida and Arizona were all red states that voted for Trump. In 2020, those same states will have robust adult-use and/or medical marijuana programs.

Hemp

Hemp is inextricably tied to our country’s history. After all, George Washington himself grew it at Mount Vernon. With the 2018 Farm Bill legalizing the cultivation of hemp, analysts suggest that hemp could boost local economies and has the potential to grow into a multi-billion industry. Legalizing hemp will allow more jobs and more products to be created here in the U.S. The real question for 2019 is: how will the FDA regulate CBD products?

Public Markets

2018 was a year of excitement and milestones for investment in the cannabis industry. Canadian companies Cronos, Canopy Growth, and Tilray became the first “cannabis-only” stock listed on U.S. exchanges. Meanwhile, American companies MedMen, GTI and Acreage — unable to list in the United States due to conflicts between federal and state laws — listed on the Canadian Stock Exchange. The ironic trend of U.S.-based cannabis companies looking north to Canadian exchanges and Canadian companies looked South to U.S. exchanges will continue in 2019.

Perhaps the most important trend likely to continue in 2019 is the dissipating stigma around cannabis. Opinions change quickly when people see their own family and friends using cannabis. Consider the grandmother using cannabis to help alleviate chronic pain, one’s veteran brother-in-law using cannabis to more effectively deal with PTSD or even one’s next door neighbor that uses cannabis responsibly on the weekend to relax and unwind.

As cannabis is drawn further from the shadows, state and federal policy changes, hemp production and IPOs all become easier to accomplish. In 2019, we’re poised to see more positive steps in that direction.

Read the full article here: https://www.greenentrepreneur.com/article/325999

Statement from Vireo Health on Cuomo’s State of the State Address and Legalization of Adult-use Marijuana

VIEW ALL NEWS

Vireo Health of New York CEO Ari Hoffnung testifies on adult-use cannabis

VIEW ALL NEWS

Vireo Health and Local 338 RWDSU/UFCW announce discount program for NY union members

VIEW ALL NEWS

Statement from Vireo Health on Department of Health’s Decision to Improve Patient Access to Medical Marijuana for New Yorkers Prescribed Opioids

The following statement regarding New York State’s plan to allow medical cannabis to be used as an alternative to prescription opioids can be attributed to Dr. Stephen Dahmer, Chief Medical Officer of Vireo Health, one of only 10 organizations licensed in the state to grow, cultivate, manufacture and sell medical cannabis:

“Today’s announcement made by Department of Health Commissioner Dr. Howard Zucker is an important step towards potentially helping thousands of New Yorkers that rely on opioid-based medications to treat their pain. We are fully prepared to work collaboratively with the Department to improve medical cannabis access and support for more New Yorkers who can benefit from these medicines.”

###

 

About Vireo Health of New York

Vireo Health of New York is a physician-led company dedicated to providing best-in-class cannabis-based medications and compassionate care. The Company is a proven leader in the field of medical marijuana. In December 2015, Vireo’s products became the first to be certified Kosher by the Orthodox Union. In addition to brick-and-mortar dispensary locations, Vireo launched the first medical marijuana home delivery service in the New York City area, now available throughout New York City, Westchester, Rockland, Nassau and parts of Suffolk County. For more information, visit https://vireohealth.com/ny/.

Vireo Health to Participate in $3.8 million NIH Study on Medical Marijuana, Pain and Opioid Use

VIEW ALL NEWS

Vireo Announces Free Medical Marijuana Home Delivery

VIEW ALL NEWS

Vireo launches first marijuana ad campaign in nyc subway history

VIEW ALL NEWS

Vireo to Expand Home Delivery of Medical Marijuana to Bronx, Staten Island and Westchester

Vireo to Expand Home Delivery of
Medical Marijuana to Bronx, Staten Island and Westchester

Delivery currently exists in Brooklyn, Queens, Nassau and parts of Suffolk County

New York, NY –Vireo Health of New York (“Vireo”), one of only five companies licensed by New York State to cultivate, manufacture and dispense medical marijuana, will expand its groundbreaking medical marijuana home delivery program to the Bronx, Staten Island and Westchester County beginning on Saturday, May 6.

“We are rapidly expanding our delivery capabilities to reach more of the New York City metro area,” said Ari Hoffnung, CEO of Vireo Health of New York. “Our delivery program has seen great success over the last few weeks, serving not only those patients who are home-bound or have trouble visiting a dispensary but also those who appreciate its convenience.”

Last month, medical marijuana home deliveries started in Brooklyn, Queens, Nassau and parts of Suffolk County. The delivery zone will then expand into Manhattan. Over time, Vireo hopes to cover other areas throughout New York State, particularly in the Capital Region and Southern Tier.

The medical marijuana ‘from our greenhouse to your front door’ home delivery program was designed by a team of security experts, pharmacists and physicians to serve homebound patients with life-threatening and debilitating diseases, like Cancer, ALS and chronic pain.

Numerous measures have been taken to ensure the safety of patients and the delivery staff. In accordance with State regulations that prohibit outsourcing in New York’s ‘seed-to-sale’ medical marijuana industry, all deliveries will be handled exclusively by Vireo employees. The deliveries will be made by at least two employees, and company-owned delivery vehicles are outfitted with cutting-edge safety features, including GPS tracking devices.

Qualifying patients can register for the home delivery program online and use coupon code REGONLINE to receive a $10 discount off their first online order.

Additional information about the home delivery program is available at vireohealth.com/ny/delivery.

###

 

About Vireo Health of New York
Vireo Health of New York is a physician-led company dedicated to providing best-in-class cannabis-based medications and top quality patient care. The company provides a wide array of pharmaceutical grade cannabis-based products formulated from the highest quality plants and utilizes its separation chemistry capabilities to create products with novel cannabinoid combinations. Vireo Health of New York is a wholly owned subsidiary of Vireo Health, LLC. For more information, visit http:/www.vireohealth.com/ny.